Expected results from clinical study
Eurocine Vaccines expect to present the results from the ongoing PhaseI/II study with the the first product candidate Immunose™ FLU.
Eurocine Vaccines expect to present the results from the ongoing PhaseI/II study with the the first product candidate Immunose™ FLU.
Share our ambition developing more effective vaccines. Fill in your e-mail address and we will update you with the latest Press Releases and Stories.